Susan Altschuller | Alexion Pharmaceuticals, Inc. |
Ludwig N. Hantson | Alexion Pharmaceuticals, Inc. |
Paul J. Clancy | Alexion Pharmaceuticals, Inc. |
John J. Orloff | Alexion Pharmaceuticals, Inc. |
Brian Goff | Alexion Pharmaceuticals, Inc. |
Geoffrey C. Porges | Leerink Partners LLC |
Matthew K. Harrison | Morgan Stanley & Co. LLC |
Terence Flynn | Goldman Sachs & Co. LLC |
Josh Schimmer | Evercore, Inc. |
Christopher J. Raymond | Piper Jaffray & Co. |
Anupam Rama | JPMorgan Securities LLC |
Jason Zemansky | Barclays Capital, Inc. |
Phil Nadeau | Cowen & Co. LLC |
Martin Auster | Credit Suisse Securities (NYSE:USA) LLC |
Keith Mackey | RBC Dominion Securities, Inc. |
Ying Huang | Bank of America Merrill Lynch |
Robyn Karnauskas | Citigroup Global Markets, Inc. |
Hartaj Singh | Oppenheimer & Co., Inc. |
Yatin Suneja | SunTrust Robinson Humphrey, Inc. |
Good morning, and welcome to the Alexion Pharmaceuticals, Incorporated Second Quarter 2018 Results Conference Call. Today's call is being recorded.
For opening remarks and introductions, I would now like to turn the call over to Susan Altschuller, Vice President, Investor Relations. Go ahead, ma'am.
Thank you, Gigi.